Definium (DFTX) news
Recent news
Definium Therapeutics shares up 2.2% after JP Morgan initiates coverage with overweight rating
Definium Therapeutics Inc. (NASDAQ: DFM) shares rose 2.2% in early trading on October 9, 2026, following an initiation of coverage by JP Morgan, which assigned the stock an "overweight" rating [1]. The firm cited the company’s progress in its clinical pipeline and potential for long-term growth as…
AInvest Wire · 6d agoDefinium Therapeutics shares up 4% premarket after JP Morgan initiates coverage with overweight rating
Definium Therapeutics Inc. (NASDAQ: DFM) shares rose 4% in premarket trading on October 9, 2026, following an initiation of coverage by JP Morgan, which assigned an "overweight" rating to the stock. The firm cited the company’s progress in its clinical pipeline and potential for long-term growth as…
AInvest Wire · 6d agoDefinium Therapeutics Inc: Leerink partners raises target price to $70 from $52
Leerink Partners has revised its price target for Definium Therapeutics Inc (NASDAQ: DFTX), raising it to $70 from a previous estimate of $52, according to recent updates. The adjustment reflects the firm’s updated assessment of the company’s prospects and ongoing developments in its therapeutic…
AInvest Wire · Sep 14, 2026Definium Therapeutics shares jump 20% premarket after co's LSD-based drug lowers anxiety in second successful late-stage study
Definium Therapeutics Inc. reported positive results from a second late-stage clinical trial of its LSD-based therapy for anxiety, leading to a 20% increase in its shares before market open on September 14, 2026. The company stated that the treatment demonstrated statistically significant…
AInvest Wire · Sep 14, 2026Definium Therapeutics shares halted due to pending news
Definium Therapeutics Inc. (NASDAQ: DFM) announced on September 14, 2026, that trading of its shares has been temporarily halted due to the company’s intention to release material news. The stock was suspended at the open of trading, and no further transactions are permitted until the pending…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.